Evidence map›Paper›PMID 42845513›Full record

ArticlebioRxiv : the preprint server for biology2026

'An

Perry Chien, Brendan F Kohrn, Megan Nguyen, Timothy J Martins, Samuel Emerson, Scott R Kennedy, Raymond J Monnat

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Perry ChienAllen School of Computer Science and Engineering, University of Washington, Seattle WA.
Brendan F KohrnLaboratory Medicine and Pathology, University of Washington, Seattle WA.ORCID 0000-0001-9948-2131
Megan NguyenLaboratory Medicine and Pathology, University of Washington, Seattle WA.
Timothy J MartinsInstitute for Stem Cell and Regenerative Medicine, University of Washington, Seattle WA.ORCID 0000-0002-2133-7281
Samuel EmersonNeurological Surgery, University of Washington, Seattle WA.ORCID 0009-0009-1994-2878
Scott R KennedyLaboratory Medicine and Pathology, University of Washington, Seattle WA.ORCID 0000-0002-4444-1145
Raymond J MonnatLaboratory Medicine and Pathology, University of Washington, Seattle WA.ORCID 0000-0001-7638-7393

Funding

Understanding the regulation of mtDNA heteroplasmy and integrityR35GM153370 · NIGMS · UNIVERSITY OF WASHINGTON · PI Scott Robert Kennedy · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM153370
6 · The paper itself

Abstract

Background: Meningiomas are the most common primary nervous system neoplasm in adults. There are few good cellular models, especially of high grade/malignant meningiomas, to use to identify new therapeutic agents and treatment regimens. The widely available, partially characterized, Methods: We generated new data to better characterize IOMM-Lee genomic and mtDNA variants, proliferation rate and colony-forming efficiency and sensitivity to ionizing radiation as a function of ATM kinase activity. A screen of 349 anti-cancer drugs identified multiple, mechanistically distinct clinical use drugs with nanomolar IC Results: Exome sequencing confirmed that IOMM-Lee is Importance of the Study: We provide new data to better characterize IOMM-Lee, the most widely used cell line model of human Grade 3 malignant meningioma. These data identify and characterize IOMM-Lee genomic alterations and mtDNA variants; quantify growth kinetics and ionizing radiation sensitivity; and identify multiple mechanistically distinct, clinical use drugs with nanomolar IC

Indexed as

high throughput drug screenionizing radiationmeningioma cell linenuclear and mtDNA genomic variantsproliferation kinetics

Identifiers

PMID42845513
PMCPMC13640685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.